Anti-edema agent

Details Anti-edema agent Anti-edema agent

1999-11-05

2001-05-29

Caputa, Anthony C. (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C514S002600, C514S021800

Reexamination Certificate

active

06238665

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to suppression of edema formation and suppression against an increase of vascular permeability of the blood-brain barrier using an anti-edema agent containing histamine-added immunoglobulin as an effective component.
BACKGROUND OF THE INVENTION
A complex of immunoglobulin and histamine has been known as a drug preparation, histamine-added immunoglobulin. It restores histamine fixing ability which is lowered in patients suffering from allergy and asthma. Accordingly, histamine-added immunoglobulin is used as an agent for nonspecific hyposensitizing therapy for bronchial asthma, allergic rhinitis, vasomotor rhinitis and allergic skin diseases such as urticaria, chronic eczema, atopic dermatitis, etc. Histamine-added immunoglobulin also exhibits suppressive action to liberation of histamine. It does not exhibit side effects exhibited by antihistamines and adrenocortical hormones used as symptomatic remedies. It has therefore been widely used as a pharmaceutical agent with high safety. See pages 463 and 464 of “Drugs in Japan, Ethical Drugs,” edited by Japan Pharmaceutical Information Center; published by Yakugyo Jiho Co., Ltd., Japan in October 1996.
In addition to said medical indications, it has been reported that histamine-added immunoglobulin has a suppressive action against hypereosinophilicity, immunomodulating action and the like, and the oral administration of histamine-added immunoglobulin expresses the same pharmacological activity as shown by usual hypodermic injection. See, for example, Japanese Laid-Open Patent Publications Hei-7/53406, and Hei-9/31311. However, there has been no report regarding a suppressive action against edema formation and a suppressive action against an increase of vascular permeability of the blood-brain barrier which is exhibited by histamine-added immunoglobulin.
The present inventor has conducted an extensive investigation on histamine-added immunoglobulin and found that it also has a suppressive action against edema and a suppressive action against an increase of vascular permeability of the blood-brain barrier. The present invention provides an anti-edema agent, a suppressive agent against edema formation, and a suppressive agent against an increase of vascular permeability of the blood-brain barrier containing histamine-added immunoglobulin as an effective component. The anti-edema and suppressive agents have a high degree of safety with little side effects.
SUMMARY OF THE INVENTION
Edema, edema formation, and an increase of vascular permeability of the blood-brain barrier are substantially suppressed by administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutically effective amount of a histamine-added immunoglobulin and a pharmaceutically acceptable carrier. The histamine-added immunoglobulin may be prepared by dissolving about 1 mg to about 200 mg, preferably about 5 mg to about 50 mg, of immunoglobulin and about 0.01 &mgr;g to about 2 &mgr;g, preferably about 0.05 &mgr;g to about 0.5 &mgr;g, of a histamine component in a pharmaceutically acceptable solution.


REFERENCES:
patent: 3873697 (1975-03-01), Filipp et al.
patent: 4704273 (1987-11-01), McMichael
patent: 4705685 (1987-11-01), McMichael
patent: 4705687 (1987-11-01), Lau
patent: 4812449 (1989-03-01), Rideout
patent: 5112738 (1992-05-01), Buckler et al.
patent: 5354848 (1994-10-01), Faligiani et al.
patent: 5622970 (1997-04-01), Armistead et al.
patent: 5639758 (1997-06-01), Sharpe et al.
patent: 5780026 (1998-07-01), Yoshii et al.
patent: 196 34 537 (1998-03-01), None
patent: 0 758 656 A2 (1967-02-01), None
patent: 0 646 376 A1 (1995-04-01), None
patent: 0 864 323 (1998-09-01), None
Naiki M. et al., “Rat Gamma Globulin/Hisstamine Inhibits Experimental Allergic Encephalomyelitis (EAE) In Lewis Rats,”International Congress of Immunology Abstracts,Jul. 23, 1995, XP000672330.
Yoshii H. et al., “A complex of histamine mouse gamma-globulin preferentially inhibits allergen-induced peritoneal accumulation of eosinophils, but not neutrophils, in mice,”Journal of Allergy and Clinical Immunology,(Dec. 1997) 100 (6 PT 1), 809-16, XP000876581.
Kagoshima, M. et al.,Inflamm. res.,vol. 46, pp. 147-153 (1997).
Elwany, Samy et al.,The Journal of Laryngology and Otology,vol. 111, pp. 935-940 (Oct., 1997).
Pop, S. et al., “Follow-up of the THG therapeutic action” Chemical Abstracts Service No. 89-140377 HCA XP002130193. Farmacia (Bucharest) (1978), 26 (1), pp. 9-12.
M. Naiki et al., “Neurotropin Inhibits Experimental Allergic Encephalomyelitis (EAE) In Lewis Rats”,Int. J. Immunopharmac.,13(2/3), 235-243 (1991).
“Drug Evaluations Annual 1995”, American Medical Association, pp. 438-445 (1995).
Goodin, “The use of immunosuppressive agents in the treatment of multiple sclerosis: A critical review”,Neurology,vol. 41, pp. 980-985 (1991).
Higashiguchi, et al., Chemical Abstracts 112:111828b, 1990.
Getlik, et al., Chemical Abstracts 67, #5, 20482v, 1967.
Volokhovskaya, et al., Chemical Abstracts, 115:21847q, 1991.
Yoshii, et al., “Inhibitory Effect of Histamine-Added Mouse &ggr;-Globulin On Eosinophil Accumulation Induced By Allergen In Balb/c Mice”,Japanese Journal of Allergology,44:567-570 (1995).
Yoshii, et al., “A New Assay System Detecting Antibody Production And Delayed-Type Hypersensitivity Responses To Trinitrophenyl Hapten In An Individual Mouse”,Int. J. Immunopharmac.,vol. 18, No. 1, pp. 31-36, 1996.
Fujiwara, et al., “Sandwich enzyme immunoassay of tumor-associated antigen sialosylated Lewis using &bgr;-D-galactosidase coupled to a monoclonal antibody of IgM isotype”,Journal of Immunological Methods,112, pp. 77-83, 1988.
Burnham, “Polymers for delivering peptides and proteins”,Am J Hosp Pharm,vol. 51, pp. 210-218, Jan. 15, 1994.
Wood, et al., Biochemistry A Problems Approach, 2nd edition, pp. 155-156, 1981.
Naiki, et al., 9th International Congress of Immunology, p. 183, abstract 1084, Jul. 23-29, 1995.
Kaneko, et al., “Role of Interleukin-5 in Local Accumulation of Eosinophils in Mouse Allergic Peritonitis,”Int. Arch Allergy Appl Immunol.,1991; 96: 41-45.
Kaplan A.P.,Allergy,second edition, 1977, pp. 148-178, 260-261, 426-427, 439-440, 456-457, 482-483, 554, 597-598, 861-875.
Roitt, I. et al, “Hpersensitivity—Type IV”,Immunology,2nd ed., 1989, pp. 22.1-22.10.
Dunn, C. J., et al., “Murine Delayed-Type Hypersensitivity Granuloma: An Improved Model For The Identification And Evaluation Of Different Classes Of Anti-Arthritic Drugs,”Int. J. Immunopharmac.,vol. 12, No. 8, pp. 899-904, 1990.
Yu, M., et al., “Interferon-&bgr; inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis,”Journal of Neuroimmunology64 (1996), pp. 91-100.
Arnason, “Interferon Beta in Multiple Sclerosis,”Clinical Immunology and Immunopathology,vol. 81, No. 1, Oct., pp. 1-11, 1996.
The Merck Index, Twelfth Edition, 1996, p. 807.
Sigma Biochemicals Organic Compounds for Research and Diagnostic Reagents,1995, pp. 470-472, and 1365-1368.
Curtis, et al.,Biology,Fifth edition, Worth Publishers (New York), 1989, pp. 835-836.
Atton-Chamla et al., “Premenstrual syndrome and atopy: a double-blind clinical evaluation of treatment with a gamma-globulin/histamine complex,”Pharmatherapeutica,vol. 2, No. 7, 1980, pp. 481-486.
Tanizaki et al., “Inhibitory Effect of Histamine-Gamma Globulin Conjugate on IgE-Mediated Reactivity of Human Basophils,”Jpn. J. Allergol.33, (12), pp. 1025-1029, 1984.
Peacock, Jr., E. E.,Wound Repair,Third Edition, W. B. Saunders Co., 1984, pp. 96-97.
Fahey et al., “Status of Immune-based therapies in HIV infection and AIDS,”Clin. exp. Immunol.(1992) 88, 1-5.
Fundamental Immunology,Third Edition, W. E. Paul, Editor, Raven Press, 1993, pp. 1354-1369.

Affiliated with

Also associated with

Rating

Anti-edema agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-edema agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-edema agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2519090